Powered by BiozApplication to, and approval by, the Framingham Heart Study is necessary to receive these cell lines.
An additional clone (FHS068i-sh9462B) is available from WiCell.
The donor this cell line is derived from is part of the Framingham Heart Study (FHS) Offspring, Exam 9 or Omni I, Exam 4 Cohort. Inclusion in the Framingham Heart Study is population rather than diagnosis based, and therefore no information on health status is listed publicly. All phenotypic and genotypic data on Framingham subjects is available at dbGaP (see link below), and can be reviewed with appropriate permissions. Full medical history is available following application to, and approval from, the Framingham Heart Study.
- Unit of Measure (UOM) Vial
- Cell Type Human iPS
- Sex Female
- Age at Collection 71-80 Years
- Ethnicity Information Self-reported
- Reprogramming Method Non-integrating (Sendai: Oct3/4, Sox2, Klf4, cMyc)
- Tissue Origin Peripheral Blood Mononuclear Cell
- Ethnicity Caucasian
- Pubmed Abstract Warren, C et al. "Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease." Cell Stem Cell 20 (2017): 547-557.
- dbGap Data GSM2411795 |phs000007
- Provider Harvard Stem Cell Institute - Dr. Chad Cowan
- Collections Framingham Heart Study (FHS) Collection, NHLBI Next Gen - Framingham Heart Study Collection (Dr. Chad Cowan, Harvard Stem Cell Institute)
| Lot Number | Culture Platform | Lot Description | Banked By | Passage Number | Protocol | Product Info URL |
| DB67141 | StemMACS iPS-Brew/Matrigel | Provider | 14 | WiCell Feeder Independent Pluripotent Stem Cell Protocol |